Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.
This work was performed at University of California Los Angeles Medical Center.
As the life expectancy of patients with musculoskeletal tumors improves, long-term studies of endoprosthetic reconstructions are necessary to establish realistic expectations for the implants and compare them to other reconstruction approaches.
(1) What is the long-term survival of cemented bipolar proximal femoral replacements? (2) How does prosthesis survival compare to patient survival among patients with Stage I, II, and III disease? (3) Do modular implants outperform custom-built prostheses? (4) Do some proximal femoral replacements require conversion to THA?
We retrospectively reviewed all 86 proximal femoral replacements used for tumor reconstruction from 1982 to 2008. Primary diagnoses were 43 high-grade tumors (IIA/IIB), 20 low-grade tumors (IA/IB or benign), and 23 with metastatic disease. We reviewed prosthesis survival, patient survival, complication rates, functional outcomes, and rates of conversion to THA.
Five of 86 patients (5.8%) required revision of the femoral component. Five-, 10-and 20-year implant survivorships were 93%, 84%, and 56%, respectively. All patients with low-grade disease survived; the 5-year survival rate for patients with metastatic disease was 16%; the 5-, 10-, and 20-year survival for IIA/IIB patients was 54%, 50%, and 44%, respectively. Five of 86 patients (5.8%) underwent conversion to THA for groin pain.
Cemented bipolar proximal femoral replacements after tumor resection proved a durable reconstruction technique. The implants outlived patients with metastatic disease and high-grade localized disease while patients with low-grade disease outlived their implants. The survival of modular prostheses was comparable to that of older, one-piece custom designs.
Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Brien EW, Terek RM, Healy JH, Lane JM. Allograft reconstruction after proximal tibial resection for bone tumors: an analysis of function and outcome comparing allograft and prosthetic reconstructions. Clin Orthop Relat Res. 1994;303:116–127. PubMed
Cabanela ME. Bipolar versus total hip arthroplasty for avascular necrosis of the femoral head: a comparison. Clin Orthop Relat Res. 1990;261:59–62. PubMed
Cannon CP, Zeegan E, Eckardt JJ. Techniques in endoprosthetic reconstruction. Oper Tech Orthop. 2005;14:225–235. CrossRef
Eckardt JJ, Eilber FR. Endoprosthetic replacement. Curr Orthop. 1993;7:148–156. CrossRef
Eckardt JJ, Eilber FR, Grant TO, Mirra JM, Weisenberger TH, Dorey FJ. Management of Stage IIB osteogenic sarcoma: experience at the University of California, Los Angeles. In: Cancer Treatment Symposia. Vol 3. National Institutes of Health Publication Number 85-2766. Bethesda, MD: National Institutes of Health; 1985:117–130.
Enneking WF. Modification of the system for functional evaluation of surgical management of musculoskeletal tumors. In: Limb Salvage in Musculoskeletal Oncology. Enneking WF, ed. New York, NY: Churchill Livingstone; 1987:626–639.
Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120. PubMed
Horowitz SM, Glasser DB, Lane JM, Healey JH. Prosthetic and extremity survivorship after limb salvage for sarcoma: how long do the reconstructions last? Clin Orthop Relat Res. 1993;293:280–286. PubMed
Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–481. CrossRef
Lange B, Kramer S, Gregg J, Toledano S, Wimmer R, Evans A. High-dose methotrexate and Adriamycin in osteogenic sarcoma: The Children’s Hospital of Philadelphia Study. Am J Clin Oncol 1982;5:3–8. PubMed
Lieberman JR, Dorey F, Shakelle P, Schumaker L, Thomas BJ, Kilgus DJ, Finerman GA. Differences between patients’ and physicians’ evaluations of outcome after total hip arthroplasty. J Bone Joint Surg Am. 1996;78:835–888. PubMed
Machin D, Palmar MKB. Comparison of 2 survival curves. In Machin D, Palmar MKB, eds. Survival Analysis: A Practical Approach. Chichester, England: Bookcraft; 1995:66–75.
Malawar MM, Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am. 1995;77:1154–1165.
Moore AT, Bohlman HR. Metal hip joint: a case report. J Bone Joint Surg Am. 1943;25:688–692.
Springfield DS, Enneking WF, Neff JR, Makley JT. Principles of tumor management. Instr Course Lect. 1984;33:1–25. PubMed
- How Long Do Endoprosthetic Reconstructions for Proximal Femoral Tumors Last?
MD Nicholas M. Bernthal
MD Adam J. Schwartz
MD Daniel A. Oakes
PhD J. Michael Kabo
MD Jeffrey J. Eckardt
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II